ACTR-33. INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY
Andrew B. Lassman(Columbia University), Patrick Roth(University Hospital of Zurich), Patrick Y. Wen(Dana-Farber Cancer Institute), Cristóbal Belda-Iniesta(Instituto de Salud Carlos III), Steven Rowsey(Rapt Therapeutics (United States)), Filip De Vos(University Medical Center Utrecht), Vinay K. Puduvalli(The University of Texas MD Anderson Cancer Center), Keith Steward(QED Technologies (United States)), Jeffrey Raizer(Northwestern University), Timothy F. Cloughesy(University of California, Los Angeles), Yining Ye(QED Technologies (United States)), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Nicholas Butowski(University of California, San Francisco), Paul M. Clément(Universitair Ziekenhuis Leuven), Morris D. Groves(Texas Oncology), Juan Gil-Gil(Duran i Reynals Hospital)
Cited by 8
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k